Evaluation of general anesthesia protocols for a highly controlled cardiac ischemia-reperfusion model in mice.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 15 04 2024
accepted: 20 08 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

The aim of our study was to test different anesthetic mixtures in order to identify the most suitable one for a surgical cardiac ischemia-reperfusion model in mice. 1) Sixty four mice were submitted to one of the 6 combinations of ketamine or alfaxalone associated to xylazine, medetomidine or midazolam. Depth and quality of anesthesia were evaluated via 5 reflex scores. 2) Impact of analgesic (buprenorphine or butorphanol), anesthesia reversal (with atipamezole) and surgery (cardiac ischemia-reperfusion surgery) have been tested in the selected protocols. 3) infarction size has been measured with TTC (Triphenyl Tetrazolium Chloride) method in mice anesthetized with best protocols. Protocol involving medetomidine induced the longest surgical anesthesia: (median = 120, {interquartile range = 100-125}) min with ketamine and 53 {25-100} min with alfaxalone. Butorphanol substitution with buprenorphine did not alter time-related anesthesia parameters. Atipamezole reversal considerably reduced both recovery and immobilization time (respectively 22 {18-30} min and 98 {88-99} min vs. 55 {40-70} min and 143 {131-149} min, in groups with no reversal, p = 0.001) with no impact on infarction size measurement. In this study, the combination alfaxalone/medetomidine/buprenorphine (80/0,3/0,075 mg.kg-1, s.c.) associated with reversal by atipamezole was a reliable anesthetic protocol for murine surgery, particularly for the study of ischemia-reperfusion.

Sections du résumé

BACKGROUND BACKGROUND
The aim of our study was to test different anesthetic mixtures in order to identify the most suitable one for a surgical cardiac ischemia-reperfusion model in mice.
METHODS METHODS
1) Sixty four mice were submitted to one of the 6 combinations of ketamine or alfaxalone associated to xylazine, medetomidine or midazolam. Depth and quality of anesthesia were evaluated via 5 reflex scores. 2) Impact of analgesic (buprenorphine or butorphanol), anesthesia reversal (with atipamezole) and surgery (cardiac ischemia-reperfusion surgery) have been tested in the selected protocols. 3) infarction size has been measured with TTC (Triphenyl Tetrazolium Chloride) method in mice anesthetized with best protocols.
RESULTS RESULTS
Protocol involving medetomidine induced the longest surgical anesthesia: (median = 120, {interquartile range = 100-125}) min with ketamine and 53 {25-100} min with alfaxalone. Butorphanol substitution with buprenorphine did not alter time-related anesthesia parameters. Atipamezole reversal considerably reduced both recovery and immobilization time (respectively 22 {18-30} min and 98 {88-99} min vs. 55 {40-70} min and 143 {131-149} min, in groups with no reversal, p = 0.001) with no impact on infarction size measurement.
CONCLUSION CONCLUSIONS
In this study, the combination alfaxalone/medetomidine/buprenorphine (80/0,3/0,075 mg.kg-1, s.c.) associated with reversal by atipamezole was a reliable anesthetic protocol for murine surgery, particularly for the study of ischemia-reperfusion.

Identifiants

pubmed: 39453969
doi: 10.1371/journal.pone.0309799
pii: PONE-D-24-13742
doi:

Substances chimiques

Ketamine 690G0D6V8H
Medetomidine MR15E85MQM
Xylazine 2KFG9TP5V8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0309799

Informations de copyright

Copyright: © 2024 Leon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Christelle Leon (C)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Alice Ruelle (A)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Juliette Geoffray (J)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Lionel Augeul (L)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Catherine Vogt (C)

Université-Lyon, Ecole de Chirurgie et de Gestes Micro-Invasifs de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Pascal Chiari (P)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Service d'Anesthésie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France.

Ludovic Gomez (L)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Michel Ovize (M)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Gabriel Bidaux (G)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Bruno Pillot (B)

Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Département de Cardiologie, Hospices Civils de Lyon, Groupement Hospitalier EST, IHU-OPERA Bâtiment B13, Bron, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH